Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9Y2Z4: Variant p.Phe52Leu

Tyrosine--tRNA ligase, mitochondrial
Gene: YARS2
Feedback?
Variant information Variant position: help 52 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Phenylalanine (F) to Leucine (L) at position 52 (F52L, p.Phe52Leu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and aromatic (F) to medium size and hydrophobic (L) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In MLASA2; has a 2-fold reduction in catalytic activity and a reduction in affinity for tRNA-tyr resulting in an overall 9-fold loss of catalytic efficiency. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 52 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 477 The length of the canonical sequence.
Location on the sequence: help HSGAQGLLAAQKARGLFKDF F PETGTKIELPELFDRGTASF The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         HSGAQ--------GLLAAQKARGLFKDFFPETGTKIELPEL-----FDRGTAS-F

Mouse                         RPGAR--------GMLVAPRARGLFKEFFPESGTKTELPEL

Rat                           RPGAR--------GMLVAPRARGLFKEFFPESGTKTELPEL

Drosophila                    ---SQ--------KNLLELTDRGFFHGIFPDTAAP-RMKQL

Slime mold                    RPFCSTITKNDKNNVINILKKRGFIHQMTASDIEMIKMTST

Baker's yeast                 VQGTS---DSRSDNILDELKQRGLVSQV--------SQPES

Fission yeast                 ----------------KQLQARSLIHN-----------TTL
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 17 – 477 Tyrosine--tRNA ligase, mitochondrial
Beta strand 50 – 52



Literature citations
Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia--MLASA syndrome.
Riley L.G.; Cooper S.; Hickey P.; Rudinger-Thirion J.; McKenzie M.; Compton A.; Lim S.C.; Thorburn D.; Ryan M.T.; Giege R.; Bahlo M.; Christodoulou J.;
Am. J. Hum. Genet. 87:52-59(2010)
Cited for: VARIANT MLASA2 LEU-52; CHARACTERIZATION OF VARIANT MLASA2 LEU-52;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.